Skip to main content

Table 3 Incidence rate and severity of adverse events in maintenance therapy

From: Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study

Adverse events Grade Cases (incidence rate %)
Leukopenia Grade 1–2 27 (38.03%)
Grade 3–4 19 (26.76%)
Neutropenia Grade 1–2 23 (32.39%)
Grade 3–4 12 (16.90%)
Thrombocytopenia Grade 1–2 17 (23.94%)
Grade 3–4 7 (9.86%)
Anemia Grade 1–2 31 (43.66%)
Grade 3–4 12 (16.90%)
Nausea Grade 1–2 20 (28.17%)
Grade 3–4 3 (4.23%)
Vomiting Grade 1–2 18 (25.35%)
Grade 3–4 2 (2.82%)
Diarrhea Grade 1–2 7 (9.86%)
Grade 3–4 2 (2.82%)
Neurotoxicity Grade 1–2 4 (5.63%)
Grade 3–4 1 (1.41%)
Transaminase elevation Grade 1–2 13 (18.31%)
Grade 3–4 2 (2.82%)
Renal toxicity Grade 1–2 9 (12.67%)
Grade 3–4 3 (4.23%)
Weakness Grade 1–2 33 (46.47%)
Grade 3–4 5 (7.04%)
Rash Grade 1–2 9 (12.67%)
Grade 3–4 3 (4.23%)
Myalgia Grade 1–2 3 (4.23%)
Arrhythmia Grade 1–2 2 (2.82%)